×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Session 3: EVALUATING IMMUNOGENICITY OF BIOSIMILARS: WHY IT MATTERS
Session Chair(s)
Paul Chamberlain
Biopharmaceuticals & Immunogenicity Expert
NDA Advisory Board, United Kingdom
Speaker(s)
10 Years’ Experience with Biosimilars – what are the learnings?
Paul Chamberlain
NDA Advisory Board, United Kingdom
Biopharmaceuticals & Immunogenicity Expert
Assessing Immunogenicity – a risk-based approach?
Christian Schneider, DrMed
PharmaLex, Denmark
Head of Biopharma Excellence and Chief Medical Officer (Biopharma)
Immunogenicity Issues and Assessment Strategy for Biosimilar Development
Patrick Liu, MD, PhD
Teva Pharmaceuticals, Inc. , United States
Senior Director
Immunogenicity: Industry perspectives
Harald Weber, MD
F. Hoffmann-La Roche AG, Switzerland
Group International Medical Director Biopharmaceuticals
Have an account?